R&D Portfolio Management, VC-Style
This article was originally published in Start Up
Take a group of R&D executives and give them a venture fund. What you get is a fund that looks an awful lot like a pharmaceutical company's R&D portfolio. The new fund is Basel-based Biomedicines Private Equity Holding, and it's run by Jurgen Drews, MD, the former president of Roche's worldwide research; Fritz Buhler, MD, a former head of clinical research; and Stefan Ryser, Drews' former chief of staff.
You may also be interested in...
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.